Melanoma Trial, Recruiting NCT05794035 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT05794035
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 70 years or older
  • People with a performance status rated 0 to 3 on the OMS scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
  • People who have had a laboratory test confirming a type of skin cancer called invasive squamous cell carcinoma (SCC) or basal cell carcinoma (BCC)
  • People whose cancer has at least one factor that raises the risk of it coming back, such as surgical margins that were clear but very close, the location or size of the tumour, cancer cells found near nerves, a cancer that has returned, a weakened immune system, or a tumour that was deep or not well-defined
  • People for whom doctors have determined that radiation therapy to nearby lymph nodes is not needed
  • People who have not previously had radiation therapy to the area being treated
  • People who have provided written consent, or whose legal representative, trusted person, or family member has done so if the person is physically unable to sign
  • People whose doctor estimates they have a life expectancy of at least 6 months
  • People who have been assessed by a multidisciplinary medical team and found to have no medical reasons preventing surgery or radiation therapy
  • People who are enrolled in a social security scheme (a form of health coverage — confirm with trial site if this applies outside France)

Who may not be able to join:

  • People whose surgery left visible cancer tissue behind (known as R1 or incomplete resection)
  • People with severe dementia that would make it impossible to attend follow-up appointments
  • People facing psychological, family-related, social, geographical, or practical circumstances that would prevent them from attending treatment and follow-up visits
  • People currently being treated for another active cancer
  • People already taking part in another interventional clinical trial that could affect this study's results
  • People receiving a specific type of state medical assistance known as AME (confirm with trial site if this applies in your situation)
  • People whose freedom is restricted by a court or government decision

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1 49 81 45 22

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
17 October 2023
Est. completion
1 March 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30); QLQ-ELD14 Questionnaire; rate of Toxicity; efficacy of treatment modalities on regional recurrence (RR), at 3-year follow-up; progression-free survival (PFS); overall survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov